India plans to study effectiveness of AstraZeneca, Bharat Biotech vaccines
India's total coronavirus infections crossed 27 million on Wednesday27-05-2021
27-05-2021
AstraZeneca Pharma India Ltd - 506820 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
We are enclosing herewith Certificate dated May 4, 2021 issued by Integrated Registry Management Services Private Limited, Registrar and Transfer Agents (RTA) of the Company confirming the compliance of Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018.26-05-2021
ASTRAZENECA PHARMA INDIA LTD. - 506820 - 42Nd Annual General Meeting On August 9, 2021
Pursuant to regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors at their meeting held on May 25, 2021, inter-alai, approved the convening of the 42nd Annual General Meeting of the Company on Monday, August 9, 2021 at 3 p.m (IST) through video conferencing / other audio visual means.26-05-2021
AstraZeneca Pharma India Ltd - 506820 - Reappointment Of Statutory Auditors For Second Term
The Board of Directors of the Company at their meeting held on May 25, 2021, have, inter alia, approved the Re-appointment of M/s. Price Waterhouse & Co. Chartered Accountants LLP (ICAI Firm Registration No.304026E/E-300009), as the Statutory Auditors of the Company for a second term of five (5) years, subject to the approval of the shareholders at the ensuing Annual General Meeting (AGM), to hold office from the conclusion of 42nd AGM till the conclusion of 47th AGM. The Company has received the certificate of eligibility in accordance with Sections 139, 141 and other applicable provisions, if any of the Companies Act, 2013 read with the Rules issued thereunder, from M/s. Price Waterhouse & Co. Chartered Accountants LLP.26-05-2021
AstraZeneca Pharma India Ltd - 506820 - Announcement under Regulation 30 (LODR)-Change in Directorate
The Board of Directors of the Company at their meeting held on May 25, 2021, have, inter alia, approved the re-appointment of Ms. Revathy Ashok (DIN 00057539) as an Independent Director of the Company for a second term of 5 years with effect from December 2, 2021, subject to approval of shareholders of the Company at the ensuing 42nd Annual General Meeting. Further, in compliance with circular no. LIST/COMP/14/2018-19 and circular no. NSE/CML/2018/02 dated June 20, 2018 issued by BSE and NSE respectively, we affirm that Ms. Revathy Ashok is not debarred from holding the office of director by virtue of any SEBI order or any other such authority. Ms. Revathy Ashok is not related to any other director of the Company. A brief profile of Ms. Revathy Ashok is enclosed.26-05-2021
AstraZeneca Pharma India Ltd - 506820 - Outcome Of The Board Meeting Held On Tuesday, May 25, 2021
At the Board meeting of the Company held on Tuesday, May 25, 2021 the Board of Directors considered and approved the Audited Financial Results of the Company for the quarter and year ended March 31, 2021. The said Audited Financial Results together with the Audit report of the Statutory Auditors dated May 25, 2021 are enclosed herewith. We also confirm that the Auditor's Report is with unmodified opinion in respect of the Audited Financial Results of the Company for the financial year ended March 31, 2021. The Board meeting concluded at 4.05 p.m25-05-2021
AstraZeneca Pharma India Ltd - 506820 - Outcome Of The Board Meeting Held On Tuesday, May 25, 2021
At the Board meeting of the Company held on Tuesday, May 25, 2021 the Board of Directors considered and approved the Audited Financial Results of the Company for the quarter and year ended March 31, 2021. The said Audited Financial Results together with the Audit report of the Statutory Auditors dated May 25, 2021 are enclosed herewith. We also confirm that the Auditor's Report is with unmodified opinion in respect of the Audited Financial Results of the Company for the financial year ended March 31, 2021. The Board meeting concluded at 4.05 p.m25-05-2021
COVID-19: UK study shows AstraZeneca vaccine 80% effective against B1.617.2 variant
The Oxford/AstraZeneca two-dose vaccine is also being produced by the Serum Institute of India as Covishield and being administered among the adult population in India to protect against the deadly virus22-05-2021
Two doses of AstraZeneca vaccine 85-90% effective: Public Health England
Two doses of the Oxford/AstraZeneca vaccine are around 85 per cent to 90 per cent effective against symptomatic disease, Public Health England (PHE) has said21-05-2021